Medication background of Japanese men undergoing prostate needle biopsy: A medication profile based on the number of medications and drug classes
- 1Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
- 2Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
Abstract
Prostate cancer is common in older men, and the treatment decision depends strongly on the patient’s general condition and comorbidities. However, the medication background of men who reach prostate biopsy has rarely been described. We used a large Japanese administrative claims database (Medical Data Vision) to profile the medications of men who underwent prostate needle biopsy between April 2008 and June 2019. We examined the number of medications and the drug classes in relation to body mass index (BMI) and age. We identified 67,812 men, all aged 60 years or older. The mean number of medications was lowest at BMI 20–25 and increased toward both low and high BMI, showing a U-shaped pattern (minimum 1.44 drugs at BMI 22.0–22.5); the increase was driven mainly by high BMI. This pattern was consistent across age strata, and in a negative binomial regression adjusted for age the quadratic term of BMI remained significant (p < 0.001), with an adjusted minimum at BMI 20.5. The composition of drug classes differed by body size: metabolic drugs (antihypertensive/cardiovascular, dyslipidemia, diabetes, and hyperuricemia drugs) were more common at high BMI, whereas gastrointestinal and analgesic drugs were relatively more common at low BMI, and all classes increased with age. In conclusion, among men undergoing prostate biopsy, the number of medications was lowest at BMI 20–25 and the qualitative medication profile differed by BMI. These findings describe the medication background of this population and may inform the design of future risk-stratified or prospective studies.
Related
- Antidepressant medication use and objectively measured physical activity and sedentary behaviors in adults: A cross-sectional analysis of a nationally representative sample of Canadian adults
- Medication burden trajectories during hospitalization in older patients with hematological malignancies
- The widening medication adherence gap
- Active Psychotropic Medication Use and Clinical Correlates in Children and Adolescents with Autism Spectrum Disorder
- Antibiotic self-medication and public awareness during the 2023 Gaza war: a cross-sectional investigation
BibTeX
@article{sato2026medication,
title = {{Medication background of Japanese men undergoing prostate needle biopsy: A medication profile based on the number of medications and drug classes}},
author = {Kazuki Sato and Takashi Kawahara and Akihito Hashizume and Masanobu Yamazaki and Hiroki Ito and Teppei Takeshima and Shinnosuke Kuroda and Hiroji Uemura and Kazuhide Makiyama and Jun-Ichi Teranishi},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0354283},
url = {https://doi.org/10.1371/journal.pone.0354283},
note = {CC BY},
}
RIS
TY - JOUR
TI - Medication background of Japanese men undergoing prostate needle biopsy: A medication profile based on the number of medications and drug classes
AU - Kazuki Sato
AU - Takashi Kawahara
AU - Akihito Hashizume
AU - Masanobu Yamazaki
AU - Hiroki Ito
AU - Teppei Takeshima
AU - Shinnosuke Kuroda
AU - Hiroji Uemura
AU - Kazuhide Makiyama
AU - Jun-Ichi Teranishi
PY - 2026
DA - 2026/10/29
JO - PLOS One
DO - 10.1371/journal.pone.0354283
UR - https://doi.org/10.1371/journal.pone.0354283
AB - Prostate cancer is common in older men, and the treatment decision depends strongly on the patient’s general condition and comorbidities. However, the medication background of men who reach prostate biopsy has rarely been described. We used a large Japanese administrative claims database (Medical Data Vision) to profile the medications of men who underwent prostate needle biopsy between April 2008 and June 2019. We examined the number of medications and the drug classes in relation to body mass index (BMI) and age. We identified 67,812 men, all aged 60 years or older. The mean number of medications was lowest at BMI 20–25 and increased toward both low and high BMI, showing a U-shaped pattern (minimum 1.44 drugs at BMI 22.0–22.5); the increase was driven mainly by high BMI. This pattern was consistent across age strata, and in a negative binomial regression adjusted for age the quadratic term of BMI remained significant (p < 0.001), with an adjusted minimum at BMI 20.5. The composition of drug classes differed by body size: metabolic drugs (antihypertensive/cardiovascular, dyslipidemia, diabetes, and hyperuricemia drugs) were more common at high BMI, whereas gastrointestinal and analgesic drugs were relatively more common at low BMI, and all classes increased with age. In conclusion, among men undergoing prostate biopsy, the number of medications was lowest at BMI 20–25 and the qualitative medication profile differed by BMI. These findings describe the medication background of this population and may inform the design of future risk-stratified or prospective studies.
SN - 1932-6203
ER -